FDA's TEMPO Program Lets Some Generative AI Devices Reach Patients Early
The FDA's TEMPO pilot permits certain generative AI-based medical devices to be used by patients before formal marketing authorization. Four devices, including products from Cadence and Limbic, have been accepted into the program, allowing digital health firms to launch while the agency gathers real-world data.
Expanded Detail
EXPANDED:
The FDA's TEMPO pilot represents a shift in regulatory approach, allowing certain generative AI medical tools to enter clinical use prior to standard marketing approval. This pathway enables digital health companies to deploy their technologies in real-world settings while the agency concurrently collects performance data.
Currently, four specific devices have been
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “FDA pilot offers generative AI medical devices a path to patients before they are authorized.” Browse more stories.